Pablo Morentin Gutierrez

Title: Pablo Morentin Gutierrez: Innovator in Cancer Treatment

Introduction

Pablo Morentin Gutierrez is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development efforts. His work focuses on improving therapeutic regimens for patients battling cancer.

Latest Patents

Pablo holds a patent for a dosage regimen for the treatment of cancer. The patent details the use of AZD9833, which is administered orally once daily at a dose ranging from 25 mg to 450 mg. This treatment can be used alone or in combination with additional anti-cancer agents, such as CDK inhibitors, everolimus, or AKT inhibitors. His innovative approach aims to enhance the efficacy of cancer treatments and improve patient outcomes.

Career Highlights

Pablo is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to groundbreaking research in oncology. With a focus on patient-centered solutions, he continues to push the boundaries of cancer treatment.

Collaborations

Pablo has collaborated with talented colleagues, including Camila De Almeida and Eric Todd Gangl. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Pablo Morentin Gutierrez is a dedicated inventor whose work in cancer treatment exemplifies the importance of innovation in healthcare. His contributions through patents and collaborations continue to pave the way for advancements in oncology.